Search

Your search keyword '"Khadka, Sushmita"' showing total 30 results
Start Over Author "Khadka, Sushmita"
30 results on '"Khadka, Sushmita"'

1. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

Author

Zhang, Yumeng, Rose, Ashley, Khadka, Sushmita, Cao, Biwei, Eatrides, Jennifer, Saeed, Hayder, Shah, Bijal D., Chavez, Julio, Bello, Celeste, Lazaryan, Aleksandr, Khimani, Farhad, Ibarz, Javier Pinilla, Liu, Hien D., Locke, Frederick L., Jain, Michael D., Zhang, Ling, Kharfan-Dabaja, Mohamed A., Kim, Jongphil, Ayala, Ernesto, Nishihori, Taiga, and Sokol, Lubomir

Published
2024
Full Text
View/download PDF

2. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Author

Lee, Dae Hyun, Kumar, Abhishek, Mohammed, Turab, Peres, Lauren C., Alsina, Melissa, Bachmeier, Christina, Blue, Brandon J., Brayer, Jason, Chandrasekhar, Sanjay, Grajales Cruz, Ariel, De Avila, Gabe, Elmariah, Hany, Faramand, Rawan, Freeman, Ciara, Jain, Michael, Khadka, Sushmita, Khimani, Farhad, Liu, Hien, Nishihori, Taiga, Oswald, Laura B., Castaneda Puglianini, Omar A., Shain, Kenneth H., Smith, Eric, Baz, Rachid C., Locke, Frederick L., Oliveira, Guilherme H., Alomar, Mohammed, and Hansen, Doris K.

Published
2023
Full Text
View/download PDF

3. Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.

Author

Graeter, Allison, primary, Castaneda Puglianini, Omar Alexis, additional, Hansen, Doris K., additional, Vazquez-Martinez, Mariola A., additional, Blue, Brandon Jamaal, additional, Khadka, Sushmita, additional, Liu, Hien, additional, Ochoa-Bayona, Jose L., additional, Freeman, Ciara L., additional, Locke, Frederick L, additional, Nishihori, Taiga, additional, Shain, Kenneth H., additional, Baz, Rachid C., additional, Alsina, Melissa, additional, and Grajales-Cruz, Ariel Felipe, additional

Published
2024
Full Text
View/download PDF

4. Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison

Author

Khadka, Sushmita, primary, Balaji, Swetha, additional, Kaur, Japjeet, additional, Solanki, Dhanshree, additional, Kasianchyk, Mariia, additional, Chowdhury, Humayra, additional, Patel, Ishani, additional, Qasim, Muhammad, additional, Desai, Maheshkumar, additional, Maiyani, Prakash, additional, Moradiya, Dharmeshkumar V, additional, Lal, Darshan, additional, Patel, Achint A, additional, and Lekkala, Manidhar, additional

Published
2023
Full Text
View/download PDF

5. PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Mohammed, Turab, primary, Shahzad, Moazzam, additional, Peres, Lauren, additional, Khadka, Sushmita, additional, Colinleitzinger, Christelle, additional, Babu, Abida, additional, Doyle, William, additional, Puglianini, Omar Castaneda, additional, Oswald, Laura, additional, De Avila, Gabe, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon, additional, Ochoa-Bayona, Jose, additional, Smith, Eric, additional, Corallo, Salvatore, additional, Khimani4, Farhad, additional, Faramand, Rawan, additional, Elmariah, Hany, additional, Lazaryan, Aleksandr, additional, Jain, Michael, additional, Liu, Hien, additional, Nishihori, Taiga, additional, Shain, Ken, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick, additional, Freeman, Ciara, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

15. sj-pdf-1-smo-10.1177_20503121211022996 – Supplemental material for Pulmonary embolism in chronic kidney disease and end-stage renal disease hospitalizations: Trends, outcomes, and predictors of mortality in the United States

Author

Singh, Jagmeet, Khadka, Sushmita, Solanki, Dhanshree, Kichloo, Asim, Shah, Harshil, Vyas, Manasee J, Chugh, Savneek, Patel, Neil, and Solanki, Shantanu

Subjects
FOS: Veterinary sciences, 111199 Nutrition and Dietetics not elsewhere classified, Cardiology, 170199 Psychology not elsewhere classified, 111799 Public Health and Health Services not elsewhere classified, 110604 Sports Medicine, FOS: Health sciences, 110306 Endocrinology, 110308 Geriatrics and Gerontology, 111099 Nursing not elsewhere classified, 111708 Health and Community Services, 160807 Sociological Methodology and Research Methods, 111702 Aged Health Care, 111403 Paediatrics, 110904 Neurology and Neuromuscular Diseases, 110203 Respiratory Diseases, 110315 Otorhinolaryngology, 70706 Veterinary Medicine, FOS: Clinical medicine, fungi, 110319 Psychiatry (incl. Psychotherapy), FOS: Sociology, FOS: Psychology, 110599 Dentistry not elsewhere classified, 110323 Surgery, 110305 Emergency Medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified, 110314 Orthopaedics
Abstract

Supplemental material, sj-pdf-1-smo-10.1177_20503121211022996 for Pulmonary embolism in chronic kidney disease and end-stage renal disease hospitalizations: Trends, outcomes, and predictors of mortality in the United States by Jagmeet Singh, Sushmita Khadka, Dhanshree Solanki, Asim Kichloo, Harshil Shah, Manasee J Vyas, Savneek Chugh, Neil Patel and Shantanu Solanki in SAGE Open Medicine

Published
2021
Full Text
View/download PDF

19. Aortitis in COVID-19

Author

Dhakal, Pravash, primary, Khadka, Sushmita, additional, Clowes, Jackie A., additional, and Chakinala, Raja Chandra, additional

Published
2021
Full Text
View/download PDF

27. Trends and outcomes of venous thromboembolism in adult hospitalizations with acute myeloid leukemia: analysis of nationwide inpatient sample from 2010 to 2014.

Author

Khadka, Sushmita, Solanki, Dhanshree, Singh, Jagmeet, Kichloo, Asim, Patel, Neil R., Sharma, Purnima, Chugh, Savneek, and Solanki, Shantanu

Subjects
ACUTE myeloid leukemia, THROMBOEMBOLISM, NOSOLOGY, HOSPITAL mortality, HOSPITAL care
Abstract

Background: Venous thromboembolism (VTE) occurs frequently in acute myeloid leukemia (AML) patients. There are no population-based studies from the United States (U.S.) analyzing this association. The study aims to analyze the trends, predictors of mortality, and outcomes of VTE in AML patients. Methods: We analyzed the publicly available Nationwide Inpatient Sample (NIS) for years 2010–2014. Hospitalizations due to AML were identified by previously validated International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes as the primary diagnosis. VTE was identified by ICD-9-CM codes as secondary diagnosis. Hospitalizations with age less than 18 years of age were excluded. The trends and outcomes were determined using Chi-squared (χ2) test and multivariate regression models. Results: From 2010 to 2014, there were 313,282 hospitalizations with a primary diagnosis of AML and 1,633 hospitalizations (0.1%) had VTE as a concurrent diagnosis. There was a significant increase in the proportion of AML hospitalizations with VTE from 0.47% in 2010 to 0.56% in 2014 (P = 0.014). Multivariable regression analysis showed that the odds of in-hospital mortality were not higher in AML hospitalizations with VTE (odds ratio [OR] 1.11; 95% confidence interval [CI] 0.81–1.52; P = 0.5) than those without VTE. Age group above 84 years carried the highest risk of mortality (OR 3.20; 95% CI 2.77–3.70; P < 0.0001) in AML-VTE patients. Black (OR 1.23; 95% CI 1.13–1.35; P < 0.0001) and uninsured patients (OR 1.50; 95% CI 1.31–1.73; P < 0.0001) were at significantly higher odds of in-hospital mortality amongst the AML-VTE hospitalizations. Conclusion: The proportion of AML hospitalizations with VTE continues to rise in the U.S. After adjusting for confounders, increasing age, Black race, and lack of insurance were found to have higher risk of in-hospital mortality in the AML-VTE cohort. The odds of in-hospital mortality in AML hospitalizations with VTE are not higher than those without VTE. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

28. Current understanding and future implications of sepsis‐induced thrombocytopenia.

Author

Ghimire, Subash, Ravi, Swapna, Budhathoki, Rasmita, Arjyal, Lubina, Hamal, Savyata, Bista, Amir, Khadka, Sushmita, and Uprety, Dipesh

Subjects
THROMBOCYTOPENIA, MEDICAL care, SEPSIS, CRITICAL care medicine, WORLD health
Abstract

Sepsis is a global health burden that needs intensive medical care. Thrombocytopenia in sepsis is well known to increase morbidity as well as mortality. Several studies have been performed both in animal models and in humans to understand the mechanism by which sepsis causes thrombocytopenia. Recent studies have shown that inhibiting thrombocytopenia improves outcomes in sepsis patients. Understanding these mechanisms to identify targets in use of newer treatment modalities besides using resuscitation measures, antibiotics and removal of thrombocytopenia inducing agent could potentially help us improve outcomes in sepsis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

29. Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy

Author

Grajales-Cruz, Ariel F., Castaneda, Omar, Hansen, Doris K., Vazquez-Martinez, Mariola A, Blue, Brandon, Khadka, Sushmita, Liu, Hien, Ochoa-Bayona, Jose L., Freeman, Ciara Louise L., Locke, Frederick L., Nishihori, Taiga, Shain, Kenneth, Baz, Rachid, and Alsina, Melissa

Abstract

Introduction: Teclistamab (TEC) received regulatory approval for the treatment of patients with Relapsed/Refractory Multiple Myeloma (RRMM) after ≥ 3 prior lines of therapy based on the results of the pivotal MajesTEC-1 trial in which such patients achieved an overall response rate (ORR) of 63%, ≥ complete response (CR) of 39%, and median progression free survival (PFS) of 11.3 months (Moreau et al. N Engl J Med2022). Patients who had received a prior B-cell maturation antigen-targeted therapy (BCMA-TT) were excluded from MajesTEC-1 trial. Data on the efficacy of TEC in patients who have received and relapsed after prior BCMA targeted therapy is lacking. Several studies have shown reduced efficacy of both FDA approved BCMA targeted chimeric antigen receptor T cell therapies (CAR-T) for myeloma, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), when administered after BCMA targeted bi-specific antibodies. There is a paucity of data on the efficacy of TEC when administered in patients who progress after ide-cel or cilta-cel. We evaluated the real-world outcomes of patients treated with standard of care (SOC) TEC after having previously received a BCMA-TT.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results